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INTRODUCTION
Heart failure with preserved ejection fraction (HFpEF) is
a clinical syndrome in which a patient has signs and
symptoms of heart failure including dyspnea, fatigue,
pulmonary rales, peripheral edema and an ejection
fraction greater than 50%. 1-4 Approximately half of
patients with heart failure have a preserved ejection
fraction.2-5 HFpEF is considered a distinct clinical entity
from other causes of heart failure with a preserved
ejection fraction such as valvular heart disease,
pericardial disease, and infiltrative cardiomyopathy.
HFpEF carries a poor prognosis, with an annual mortality
of 29% in patients discharged after an acute
decompensated heart failure admission.5 5-year survival
rates can be as poor as 50%.2 We know that patients
with HFpEF are more likely to be older, female, and have
hypertension. 3,4 Hypertension, in fact, is present in
80-90% of patients with HFpEF.3 The aim of this work is
to summarize current understanding of HFpEF and
review the latest ACC/AHA management guidelines
while highlighting studies which provide the evidence
for and against particular management strategies.

PATHOPHYSIOLOGY
The pathophysiologic mechanisms leading to HFpEF
are complex. One proposed pathway involves
understanding HFpEF within the context of a systemic
pro-inflammatory state. In HFpEF, it is the high
prevalence of co-morbid diseases such as obesity,
hypertension, and diabetes mellitus which leads to a
systemic pro-inflammatory state and causes coronary
microvascular endothelial inflammation. 6 This
inflammation leads to low protein kinase G activity in
the cardiomyocytes leading to hypo-phosphorylation of
titin favoring hypertrophy, high resting tension, and high
diastolic left ventricular stiffness.6 Decreased nitric oxide
bioavailability has also been implicated. 6 Diastolic
dysfunction can lead to elevated pulmonary venous
pressure, congestion, and symptoms of heart failure.
The presence of high diastolic filling pressure at rest or
with exertion is a hallmark of HFpEF.2 Asymptomatic
diastolic dysfunction without heart failure symptoms
carries an increased mortality, but is a separate entity
from HFpEF. 7 Heart failure with a reduced ejection
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fraction (HFrEF) is different in that it is driven by a loss of
cardiomyocytes and is characterized by ventricular
dilation.2,6 The presence of ventricular dilation is a key
factor distinguishing HFrEF from HFpEF.2

PHARMACOLOGIC MANAGEMENT
There have been numerous advances in the
pharmacologic management of HFrEF in the past 25
years related to blockade of the renin-angiotensinaldosterone system, beta blockade, neprilysin inhibition,
and even ventricular assist devices.2,3 Unfortunately,
most clinical trial data suggests that these modalities do
not alter the course of HFpEF or provide a reduction in
mortality. The 2013 ACC/AHA guideline for the
management of heart failure gives a class I recommendation that systolic and diastolic blood pressure be
controlled in patients with HFpEF.1 While control of
hypertension is therefore considered a mainstay in
management of HFpEF, there is currently no evidence
that reducing the systemic blood pressure improves
signs or symptoms of HFpEF. ACE inhibitors, ARBs,
along with beta-blockers, may be used to treat
hypertension in patients with HFpEF as a class IIa
recommendation in the ACC/AHA guideline. Data from
the ALLHAT trial showed that chlorthalidone could
reduce the incidence of new-onset HFpEF compared
with amlodipine and lisinopril, but this pertains to HFpEF
prevention rather than treatment.8 There is no evidence
in clinical studies that ACE inhibitors or ARBs improve
morbidity or mortality in patients with HFpEF. The data
is mixed with beta-blockers, with one recent metanalysis
showing no cardiovascular or all-cause mortality benefit
in patients with HFpEF. 9 Regarding aldosterone
antagonists, data from the TOPCAT trial showed that
patients treated with spironolactone had fewer hospitalizations for heart failure as compared to patients treated
with placebo, but that spironolactone did not reduce
total deaths or hospitalizations from any cause during
the study.10 The ACC/AHA gives a class IIb recommendation for the use of aldosterone antagonists like
spironolactone to decrease hospitalizations in HFpEF.1
Statins have been shown to be beneficial in some
studies. One Swedish study found that patients with
HFpEF had a one-year survival of 85% when they were

treated with statins versus 80% when not treated with
statins.11 More recently, given that impairment in nitric
oxide signaling has been implicated in the pathophysiology of HFpEF, as introduced above, investigators in
the INDIE-HFpEF trial tested the use of inhaled inorganic
nitrite delivered via a micro-nebulizer versus placebo
over a 4-week period. The patients who received the
inhaled inorganic nitrate did not demonstrate a
statistically significant improved exercise capacity.12

SYMPTOM-BASED MANAGEMENT AND
QUALITY OF LIFE
The only intervention which has consistently been
shown to improve quality of life in patients with HFpEF
as assessed by the Minnesota Living with Heart Failure
Questionnaire is exercise. 13 Referring patients to a
cardiac rehabilitation program can improve exercise
capacity.13 Weight loss can also be beneficial in obese
patients as caloric restriction has already been shown to
improve exercise capacity in patients with HFpEF.14
Maintenance of fluid balance is a pivotal part of symptom
based management of HFpEF. The 2013 ACC/AHA
guideline for the management of heart failure gives a
class I recommendation that diuretics should be used
for relief of volume overload in patients with HFpEF. 1
This recommendation is based off findings from the
CHAMPION trial in which patients had pulmonary artery
monitors implanted to monitor their hemodynamics
and providers made medication adjustments based on
this primary data.15 A number of changes were made to
diuretic medications and these patients had a reduction
in heart failure related admissions at 6 months.15

MANAGEMENT OF ATRIAL FIBRILLATION
Atrial fibrillation is very common in patients with HFpEF,
and occurs in approximately two-thirds of patients
according to a community- based study in Olmstead
County, Minnesota.16 Supraventricular arrhythmias like
atrial fibrillation and associated tachycardia are
dangerous for patients with HFpEF in that they impair
atrial contraction and diastolic filling time. Patients with
HFpEF and atrial fibrillation have an increased mortality.16
The 2013 ACC/AHA guideline recommends
management of atrial fibrillation according to published
clinical practice guidelines in patients with HFpEF which
includes either a rate control or rhythm control strategy.1

MANAGEMENT OF CORONARY
ARTERY DISEASE
Approximately two-thirds of patients with HFpEF have
coronary artery disease demonstrated by coronary
angiography.17 Patients with HFpEF and coronary artery

disease have a higher mortality.17 Revascularization of all
coronary stenoses greater than 50%, that is, complete
revascularization, may be associated with improved
outcomes in these patients. One study found that
patients with HFpEF and coronary disease who underwent
complete revascularization had less reduction in ejection
fraction at four-year follow-up echocardiography.
Furthermore, patients who underwent complete
re-vascularization by percutaneous intervention or
bypass grafting survived longer than those patients who
underwent incomplete revascularization or had no
revascularization performed. 17 Further prospective
research is needed to determine optimal management
of coronary artery disease in HFpEF. Patients with HFpEF
who have angina can be treated symptomatically with
beta-blockers or calcium channel blockers.

CONCLUSION
Optimal management of HFpEF remains unclear even
as its prevalence and economic burden continue to
increase. 2-5 Further prospective trials enrolling this
population of patients are needed. Patients with HFpEF
represent a heterogenous group and there may not be
a “one-size fit all” type of treatment, and this is likely not
the best strategy. The latest ACC/AHA guideline for
management of heart failure published in 2013
recommends symptomatic management with diuretics
and control of co-morbid disease, including
hypertension and atrial fibrillation. The evidence clearly
supports the use of exercise in patients with HFpEF to
both improve quality of life and increase exercise
capacity. Further study is needed regarding the optimal
amount and form of exercise which could be beneficial.
Spironolactone may be used in patients with HFpEF to
reduce hospitalizations related to heart failure.

KEY POINTS
1. The latest ACC/AHA guideline for management of
heart failure provides a class I recommendation that
the systolic and diastolic blood pressure be controlled
in HFpEF and that diuretics be used for relief of
volume overload.
2. Exercise is the only intervention which has been
shown to improve quality of life in patients with
HFpEF. Patients with HFpEF should be referred to a
cardiac rehabilitation program.
3. Aldosterone antagonists may be considered to
reduce future hospitalizations related to heart failure
based on current evidence.
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